The ten most commonly asked questions about stroke prevention in atrial fibrillation

Cardiol Rev. 2001 Jul-Aug;9(4):187-92. doi: 10.1097/00045415-200107000-00003.
No abstract available

Publication types

  • Review

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use
  • Aspirin / therapeutic use
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy*
  • Blood Coagulation / drug effects
  • Clinical Trials as Topic
  • Fibrinolytic Agents / therapeutic use
  • Hemorrhage
  • Heparin / therapeutic use
  • Humans
  • International Normalized Ratio / standards*
  • Risk Assessment
  • Stroke / etiology
  • Stroke / prevention & control*
  • Warfarin / adverse effects
  • Warfarin / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Anticoagulants
  • Fibrinolytic Agents
  • Warfarin
  • Heparin
  • Aspirin